Medicine and Dentistry
Systematic Review
97%
Meta-Analysis
66%
Clinical Trial
45%
Effect Size
35%
Cross Sectional Study
34%
Disease
30%
Medicine
27%
Systematic Review with Meta-Analysis
26%
Randomized Clinical Trial
26%
Lipoarabinomannan
26%
Nucleic Acid Amplification
26%
Human Immunodeficiency Virus
23%
Adherence (Medicine)
23%
Medical Device
22%
COVID-19
16%
Micturition
16%
Odds Ratio
15%
Drug Therapy
15%
Subgroup Analysis
14%
Clinical Research
14%
Randomized Controlled Trial
14%
Major Depressive Episode
13%
Duloxetine
13%
Remdesivir
13%
Proton-Pump Inhibitor
13%
Drug Screening
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Clinical Study
13%
Lung Tuberculosis
13%
Hepatitis B Virus
13%
Tenofovir
13%
Viremia
13%
Internal Medicine
13%
RNA Directed DNA Polymerase
13%
Adolescence
13%
Adverse Event
12%
Diagnosis
12%
Diagnostic Accuracy
11%
Physician
7%
Cohort Analysis
7%
Cell Count
7%
Physical Disease by Body Function
7%
Infection
7%
Intention-to-Treat Analysis
6%
Clinical Intervention
6%
Phase III and IV Trials
6%
Emergency Department
5%
Nursing and Health Professions
Systematic Review
100%
Practice Guideline
53%
Clinical Guideline
42%
Cross-Sectional Study
39%
Meta Analysis
28%
Confidence Interval
27%
Drug Therapy
27%
Lipoarabinomannan
26%
Nucleic Acid Amplification
26%
Disease
26%
Human Immunodeficiency Virus
23%
Quality Control
14%
Adverse Event
14%
Diagnosis
13%
Medical Expert
13%
Major Depression
13%
Information Retrieval
13%
Drug Screening
13%
Randomization
13%
Intimate Partner Violence
13%
Childhood Cancer
13%
Lung Tuberculosis
13%
Adolescent
13%
Bibliographic Database
13%
Diagnostic Accuracy
11%
Adherence (Medicine)
9%
Emergency Ward
8%
Telehealth
8%
Embase
7%
Medline
7%
CD4 Lymphocyte Count
7%
Physical Disease by Body Function
7%
Thorax Radiography
7%
Hospital Readmission
7%
World Health Organization
5%
Health Outcomes
5%
Prevalence
5%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
47%
HIV
36%
Clinical Trial
33%
Adverse Event
31%
Nucleic Acid
26%
Lipoarabinomannan
26%
Major Depression
26%
Clinical Study
26%
Duloxetine
26%
Chronic Hepatitis B
16%
Pharmacotherapy
15%
SARS Coronavirus
13%
Cohort Study
13%
RNA Directed DNA Polymerase
13%
Human Immunodeficiency Virus Infection
13%
Lung Tuberculosis
13%
Drug Screening
13%
Contract Research Organization
13%
Cross-Sectional Study
13%
Randomized Clinical Trial
13%
Adverse Drug Reaction
13%
Hepatitis B Virus
13%
Prevalence
13%
Remdesivir
13%
Proteinase Inhibitor
13%
Ritonavir
13%
Viremia
13%
Nonnucleoside Reverse Transcriptase Inhibitor
13%
2,5-Dimethoxy-4-iodoamphetamine
13%
Proton Pump Inhibitor
13%
Chronic Hepatitis C
13%
Tenofovir
13%
Side Effect
13%
Mixed Infection
13%
All Cause Mortality
8%
Physical Disease by Body Function
7%
Infection
7%
Number Needed to Treat
6%
Randomized Controlled Trial
6%
Virus Hepatitis
5%
